BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 30500439)

  • 21. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.
    Rubin DB; Al Jarrah A; Li K; LaRose S; Monk AD; Ali AB; Spendley LN; Nikiforow S; Jacobson C; Vaitkevicius H
    JAMA Neurol; 2020 Dec; 77(12):1536-1542. PubMed ID: 32777012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Driving the CAR to the Bone Marrow Transplant Program.
    Dave H; Jerkins L; Hanley PJ; Bollard CM; Jacobsohn D
    Curr Hematol Malig Rep; 2019 Dec; 14(6):561-569. PubMed ID: 31643018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.
    Potnis KC; Di M; Isufi I; Gowda L; Seropian SE; Foss FM; Forman HP; Huntington SF
    Blood Adv; 2023 Mar; 7(5):801-810. PubMed ID: 36342852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization of CAR T Cell Therapy in Pediatric Patients.
    Szenes V; Curran KJ
    Semin Oncol Nurs; 2019 Oct; 35(5):150929. PubMed ID: 31526551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.
    Chakraborty R; Hill BT; Majeed A; Majhail NS
    Transplant Cell Ther; 2021 Mar; 27(3):222-229. PubMed ID: 33928266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Kallam A; Vose JM
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
    Frey NV
    Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.
    Susanibar Adaniya SP; Cohen AD; Garfall AL
    Am J Hematol; 2019 May; 94(S1):S28-S33. PubMed ID: 30730071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
    Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
    Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
    Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
    JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T.
    Akinola IM; Cusatis R; Pasquini MC; Shaw BE; Bollu V; Dalal A; Tesfaye M; Flynn KE
    Transplant Cell Ther; 2023 Apr; 29(4):254.e1-254.e9. PubMed ID: 36634738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
    Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
    J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
    Spanjaart AM; Pennings ERA; Kos M; Mutsaers PGNJ; Lugtenburg PJ; van Meerten T; van Doesum JA; Minnema MC; Jak M; van Dorp S; Vermaat JSP; van der Poel MWM; van Oijen MGH; Kuipers MT; Nijhof IS; Kersten MJ
    JCO Oncol Pract; 2023 Mar; 19(3):e407-e416. PubMed ID: 36508702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
    Munshi PN; Ujjani C
    Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.
    Dabas P; Danda A
    Med Oncol; 2023 Aug; 40(9):275. PubMed ID: 37608202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.